# Thermolesion Premarket Notification Submission





Page 122

# 510(k) Premarket Notification Submission:

### Summary of Safety and Effectiveness

Date of Preparation: July 10th, 2006

Sterilizer:

Germany

SteriPro Lab & EO Facility

Tel +49 6105 23091 or +49 (0) 6105 93470

Dreieichstrasse, 7

Fax +49 6105 24760

64546 Mörfelden

AUG 3 1 2006

Submitter Information/ production site:

Pajunk GmbH Medizintechnologie

Karl-Hall-Strasse 01 78187 Geisingen

Germany

Fon: +49(0)7704-9291-00

Fax: +49(0)7704-9291-605

Contact:

Christian Quass, Regulatory Affairs

Fon: +49(0)7704-9291-586 Fax: +49(0)7704-9291-605

E-Mail: <a href="mailto:christian.quass@pajunk.com">christian.quass@pajunk.com</a>
Establishment Registration Number:

9611612

Device Information:

Trade Names: Pajunk RFTL Radiofrequency needle

Common Name: Disposable cannula for RF Thermolesion

Classification Name: Neurological Devices: Radiofrequency lesion probe

Classification Reference: 21 CFR 882.4725, April 1. 2005

Poposed Classification: Regulatory Class II

Proposed Product Code: GXI

Predicate Devices: 1. Radionics thermo lesion needles K021942

2. Stryker's RF cannulas K032406

2006-06-27

# Thermolesion Premarket Notification Submission KO60397



### **Device Description:**

**Pajunk RFTL Radiofrequency needles** are intended for coagulation of soft tissues, such as in long term pain treatment via neurosurgical lesioning procedures, as determined by professional neurosurgeon/ anesthetist and the instructions for use. These RF-cannulas are single use, sterile, non-pyrogenic and latex free medical devices. The RF-cannulas have bevel tips with an active area of 2 – 10 mm.

The needle puncture depth depends on the path chosen by the surgeon to reach and to eliminate the nerve bundle site. This required needle length is the patient contact part of the thermolesion needle. The nerve causing constant pain will be disrupted by utilizing the thermolesion heat radiating from the needle tip. Heat is generated by radio frequency and radiates only from the non-insulated needle tip. This limited heat radiation is used for focussed heat treatment depending on the surgeon's method of operation.

#### **Predicate Devices**

Pajunk's single use anesthesia conduction needles for thermo lesion and neuro-stimulation are substantially equivalent in technique, specification, intended use, safety and effectiveness to the marketed predicate device listed above.

#### Sterilization

The contract sterilizer and the sterilizing process other than a company name change (was IBA Griffith Micro Science, and now is Sterigenics) is the same as that used for Unipolar cannulas cleared for market by FDA under 510(k) number **K000722** and Kit Products Pajunks Stimulong Set **K043130**, **K033018** and Pajunks Plexolong Set **K042979**, **K023218**, **K013041**.

#### **Packaging**

The packaging materials and procedures of Pajunk's **RFTL cannulas** are the same as those used for Unipolar cannulas cleared for market by FDA under 510(k) number **K000722** and Kit Products Pajunks Stimulong Set **K043130**, **K033018** and Pajunks Plexolong Set **K042979**, **K023218**, **K013041**.

### **Technology Characteristics**

The indications for use as well as the basic technological characteristics of Pajunk's **RFTL** cannulas are identical to Radionics thermo lesion needles **K021942** manufactured by TOP. Coating, overall cannula length and length of deinsulated tip are substantially equivalent and as safe and effective as the predicate device's.

Pajunk's **RFTL cannulas** have the same technological characteristics as the predicate device identified above.

The NanoLine coating technique Pajunks cannulas are coated with is cleared for market in Pajunks NanoLine PMN **K053283**.

#### Conclusion:

The comparison between the predicate devices and the proposed devices demonstrates that the proposed devices are safe and effective, as well as substantially equivalent to the predicate devices.





Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850

AUG 3 1 2006

Pajunk GmbH Medizintechnologie % Mr. Christian Quass Regulatory Affairs Karl-Hall-Strasse 01 78187 Geisingen, Germany

Re: K060397

Trade/Device Name: Pajunk Thermolesion Cannula "RFTL Radiofrequency Needle"

Regulatory Number: 21 CFR 882.4725

Regulatory Name: Radiofrequency lesion probe

Regulatory Class: II

Product Code: GXI, GXD Dated: July 31, 2006

Received: August 3, 2006

### Dear Mr. Quass:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to such additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the <u>Federal Register</u>.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

## Page 2 – Mr. Christian Quass

This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification. The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and thus, permits your device to proceed to the market.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please contact the Office of Compliance at (240) 276-0115. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (240) 276-3150 or at its Internet address <a href="http://www.fda.gov/cdrh/industry/support/index.html">http://www.fda.gov/cdrh/industry/support/index.html</a>.

Sincerely yours

Mark N. Melkerson

Director

Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

# Thermolesion Premarket Notification Submission



Ind	ica	tio	ns	for	use
HIIM					

510(k) Number:

K060397

**Device Name:** 

Pajunk Thermolesion Cannula "RFTL Radiofrequency Needle"

Indications for Use:

Pajunk RFTL Radiofrequency needles are electrically insulated (with lacquer or NanoLine) Cannulas, which may be used either for percutaneous nerve blocks with local anesthetic solution or for radiofrequency lesioning. The nerve is localized either by using electrical neuro-stimulation through the needle or by injecting contrast medium through the needle and using radiography concomitantly. The nerve may then be blocked by injecting local anesthetic or a radiofrequency lesion may be made.

Prescription Use\_\_\_\_X\_\_\_(Per 21 CFR 801.109)

AND/OR

Over-The-Counter Use\_\_\_\_\_(21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE IF NEEDED)

Concurrence of CDRH, Office of Device Evaluation (ODE)

invision Sign-Um)
ivision of General, Restorative,
and Neurological Devices

1 K 060397

Page 1 of 1